These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 36012390)
21. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients. Derosa L; Routy B; Fidelle M; Iebba V; Alla L; Pasolli E; Segata N; Desnoyer A; Pietrantonio F; Ferrere G; Fahrner JE; Le Chatellier E; Pons N; Galleron N; Roume H; Duong CPM; Mondragón L; Iribarren K; Bonvalet M; Terrisse S; Rauber C; Goubet AG; Daillère R; Lemaitre F; Reni A; Casu B; Alou MT; Alves Costa Silva C; Raoult D; Fizazi K; Escudier B; Kroemer G; Albiges L; Zitvogel L Eur Urol; 2020 Aug; 78(2):195-206. PubMed ID: 32376136 [TBL] [Abstract][Full Text] [Related]
22. Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma. Loo K; Smithy JW; Postow MA; Betof Warner A Front Immunol; 2021; 12():810388. PubMed ID: 35087529 [TBL] [Abstract][Full Text] [Related]
23. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma. Saito R; Sawada Y; Nakamura M Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669410 [TBL] [Abstract][Full Text] [Related]
24. An immune risk score with potential implications in prognosis and immunotherapy of metastatic melanoma. Sheng Y; Tong L; Geyu L Int Immunopharmacol; 2020 Nov; 88():106921. PubMed ID: 32871477 [TBL] [Abstract][Full Text] [Related]
26. Insignificant effects of loss of heterozygosity in HLA in the efficacy of immune checkpoint blockade treatment. Yang Y; Kim E; Kim S Genes Genomics; 2022 Apr; 44(4):509-515. PubMed ID: 35107815 [TBL] [Abstract][Full Text] [Related]
28. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
29. Strategies for improving the performance of prediction models for response to immune checkpoint blockade therapy in cancer. Zeng T; Zhang JZ; Stromberg A; Chen J; Wang C BMC Res Notes; 2024 Apr; 17(1):102. PubMed ID: 38594730 [TBL] [Abstract][Full Text] [Related]
30. Transient activation of tumoral DNA damage tolerance pathway coupled with immune checkpoint blockade exerts durable tumor regression in mouse melanoma. Zhuo M; Gorgun FM; Tyler DS; Englander EW Pigment Cell Melanoma Res; 2021 May; 34(3):605-617. PubMed ID: 33124186 [TBL] [Abstract][Full Text] [Related]
32. CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma. de Vos-Hillebrand L; Fietz S; Hillebrand P; Kulcsár Z; Diop MY; Hollick S; Maas AP; Strieth S; Landsberg J; Dietrich D Pigment Cell Melanoma Res; 2024 Mar; 37(2):309-315. PubMed ID: 37975535 [TBL] [Abstract][Full Text] [Related]
33. Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8 Watson RA; Tong O; Cooper R; Taylor CA; Sharma PK; de Los Aires AV; Mahé EA; Ruffieux H; Nassiri I; Middleton MR; Fairfax BP Sci Immunol; 2021 Oct; 6(64):eabj8825. PubMed ID: 34597125 [TBL] [Abstract][Full Text] [Related]
34. Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor. Bai X; Wang X; Ma G; Song J; Liu X; Wu X; Zhao Y; Liu X; Liu Z; Zhang W; Zhao X; Zheng Z; Jing J; Shi H Front Immunol; 2021; 12():793831. PubMed ID: 34987517 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer. Bai Y; Xie T; Wang Z; Tong S; Zhao X; Zhao F; Cai J; Wei X; Peng Z; Shen L J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35241494 [TBL] [Abstract][Full Text] [Related]
36. Combination immunotherapy strategies for glioblastoma. Chan HY; Choi J; Jackson C; Lim M J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705 [TBL] [Abstract][Full Text] [Related]
37. Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma. Park C; Na KJ; Choi H; Ock CY; Ha S; Kim M; Park S; Keam B; Kim TM; Paeng JC; Park IK; Kang CH; Kim DW; Cheon GJ; Kang KW; Kim YT; Heo DS Theranostics; 2020; 10(23):10838-10848. PubMed ID: 32929383 [No Abstract] [Full Text] [Related]
38. Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma. Takeuchi Y; Tanemura A; Tada Y; Katayama I; Kumanogoh A; Nishikawa H Int Immunol; 2018 Feb; 30(1):13-22. PubMed ID: 29294043 [TBL] [Abstract][Full Text] [Related]
39. Case Report: Sustained Remission Due to PD-1-Inhibition in a Metastatic Melanoma Patient With Depleted B Cells. Wulfken LM; Becker JC; Hayajneh R; Wagner AD; Schaper-Gerhardt K; Flatt N; Grimmelmann I; Gutzmer R Front Immunol; 2021; 12():733961. PubMed ID: 34675925 [TBL] [Abstract][Full Text] [Related]
40. Somatic mutations in DCC are associated with genomic instability and favourable outcomes in melanoma patients treated with immune checkpoint inhibitors. Li Y; Wang Q; Chen Y; Zhao L Br J Cancer; 2022 Nov; 127(8):1411-1423. PubMed ID: 35871235 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]